Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 6, pp 27–30 | Cite as

Schwerpunkt Urothelkarzinom

Harnblasenkarzinom: Aktuelle und künftige Behandlungskonzepte

  • Gunhild von AmsbergEmail author
  • Margitta Retz
  • Carsten Bokemeyer
Schwerpunkt
  • 4 Downloads

Schwerpunkt dieses Beitrag ist die Systemtherapie bei Patienten mit inoperabler lokal fortgeschrittener oder metastasierter Erkrankung. Dabei werden aktuelle und zukünftige Therapieansätze beleuchtet. Zu den Zielstrukturen für künftige Therapien zählen zum Beispiel FGFR und Nectin-4.

Literatur

  1. 1.
  2. 2.
  3. 3.
    von der Maase H et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77CrossRefGoogle Scholar
  4. 4.
    Bellmunt J et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30(10):1107–13CrossRefGoogle Scholar
  5. 5.
    Galsky MD et al. Treatment of patients with metastatic urothelial cancer „unfit“ for Cisplatinbased chemotherapy. J Clin Oncol. 2011;29(17):2432–8CrossRefGoogle Scholar
  6. 6.
    De Santis M et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatinbased chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9CrossRefGoogle Scholar
  7. 7.
    Balar AV et al. Atezolizumab as firstline treatment in cisplatinineligible patients with locally advanced and metastatic urothelial carcinoma: a singlearm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76CrossRefGoogle Scholar
  8. 8.
    Balar AV et al. Firstline pembrolizumab in cisplatinineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–92CrossRefGoogle Scholar
  9. 9.
    Grivas P PE et al. Pembrolizumab (pembro) as firstline therapy in cisplatinineligible advanced urothelial cancer (UC): outcomes from KEYNOTE-052 in senior patients. Annals of Oncology. 2017;28(suppl_5):v295–v329.  https://doi.org/10.1093/annonc/mdx371CrossRefGoogle Scholar
  10. 10.
    Bellmunt J et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61CrossRefGoogle Scholar
  11. 11.
    Fradet Yea et al. Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year followup from the phase 3 KEYNOTE045 trial. J Clin Oncol 2018;36(15_suppl):4521CrossRefGoogle Scholar
  12. 12.
    Vaughn DJ et al. Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. J Clin Oncol. 2018;36(16):1579–1587CrossRefGoogle Scholar
  13. 13.
    Sternberg CN et al. Primary Results from SAUL, a Multinational Singlearm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019; pii: S03022838(19)302015Google Scholar
  14. 14.
    Sharma P et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, singlearm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22CrossRefGoogle Scholar
  15. 15.
    SiefkerRadtke AO et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). J Clin Oncol. 2018;36(15_suppl):4503CrossRefGoogle Scholar
  16. 16.
    Rosenberg JE et al. EV201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune heckpoint inhibitor therapy. J Clin Oncol. 2018;36(15_suppl):TPS4590CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Gunhild von Amsberg
    • 1
    • 3
    Email author
  • Margitta Retz
    • 2
  • Carsten Bokemeyer
    • 1
  1. 1.II. Medizinische Klinik und Poliklinik, Onkologisches ZentrumUniversitätsklinikum Hamburg-EppendorfHamburg-EppendorfDeutschland
  2. 2.Urologische Klinik und PoliklinikKlinikum rechts der Isar der Technischen Universität MünchenMünchenDeutschland
  3. 3.Klinik für Onkologie, Hämatologie und Knochenmarkstransplantation mit Abteilung PneumologieZentrum für OnkologieHamburgDeutschland

Personalised recommendations